About BOOSTRIX
Boost your patients' protection with BOOSTRIX
BOOSTRIX provides:
- Td and pertussis protection* for the widest age range of patients (10–64 years) [9]
- Uncompromised Td immunogenicity with added pertussis protection* [9,10]
- In separate studies in adolescents and adults, anti-tetanus and anti-diphtheria seroprotective rates (≥0.1 IU/mL) for BOOSTRIX were comparable to the control Td/Tdap vaccine one month after a single dose [10]
Immunogenicity in adolescent patients
Immunogenicity in adult patients
*There are no generally accepted serologic correlates of protection for pertussis. Licensure of BOOSTRIX was based on immune responses to the vaccine and bridging to clinical efficacy data.
Indication
BOOSTRIX is indicated for active booster immunization against tetanus, diphtheria, and pertussis as a single dose in individuals 10 through 64 years of age.
Important Safety Information
- In clinical studies, common adverse events were injection-site reactions (pain, redness, swelling, or increase in arm circumference), headache, fatigue, and gastrointestinal symptoms.
- Severe allergic reaction after a previous dose of BOOSTRIX or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.
- The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurs within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine, or if progressive or unstable neurologic disorders exist.
- Persons who experienced an Arthus-type hypersensitivity reaction following a previous dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed.
- The prefilled syringes contain dry natural latex rubber that may cause allergic reactions.